The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
myo-Inositol Supplementation and Onset of Gestational Diabetes Mellitus in Pregnant Women With a Family History of Type 2 Diabetes
Open accessAbstract
OBJECTIVE: To check the hypothesis that myo-inositol supplementation may reduce gestational diabetes mellitus (GDM) onset in pregnant women with a family history of type 2 diabetes. RESEARCH DESIGN AND METHODS: A 2-year, prospective, randomized, open-label, placebo-controlled study was carried out in pregnant outpatients with a parent with type 2 diabetes who were treated from the end of the first trimester with 2 g myo-inositol plus 200 µg folic acid twice a day (n = 110) and in the placebo group (n = 110), who were only treated with 200 µg folic acid twice a day. The main outcome measure was the incidence of GDM in both groups. Secondary outcome measures were as follows: the incidence of fetal macrosomia (>4,000 g), gestational hypertension, preterm delivery, caesarean section, shoulder dystocia, neonatal hypoglycemia, and neonatal distress respiratory syndrome. GDM diagnosis was performed according to the International Association of the Diabetes and Pregnancy Study Groups (IADPSG) recommendations. RESULTS: Incidence of GDM was significantly reduced in the myo-inositol group compared with the placebo group: 6 vs. 15.3%, respectively (P = 0.04). In the myo-inositol group, a reduction of GDM risk occurrence was highlighted (odds ratio 0.35). A statistically significant reduction of fetal macrosomia in the myo-inositol group was also highlighted together with a significant reduction in mean fetal weight at delivery. In the other secondary outcome measures, there were no differences between groups. CONCLUSIONS: myo-Inositol supplementation in pregnant women with a family history of type 2 diabetes may reduce GDM incidence and the delivery of macrosomia fetuses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
International Association of Diabetes and Pregnancy Study Groups Consensus Panel (2010) · Diabetes Care · doi:10.2337/dc09-1848 · Cited by 5,390
Metzger, B. E., Gabbe, S. G., Persson, B., Lowe, L. P., Dyer, A. R., Oats, J. J. N., & Buchanan, T. A. (2010) · Diabetes Care · doi:10.2337/dc10-0719 · Cited by 1,888
The homeostasis model in the San Antonio Heart Study.
Haffner, S. M., Miettinen, H., & Stern, M. P. (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1087 · Cited by 788
Ovulatory and Metabolic Effects of d-Chiro-Inositol in the Polycystic Ovary Syndrome
Nestler, J. E., Jakubowicz, D. J., Reamer, P., Gunn, R. D., & Allan, G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401703 · Cited by 518 · cited 1×
“Another substance primarily used in polycystic ovary syndrome (PCOS), with the aim of lowering hyperinsulinemia and restoring ovarian function, was inositol; it was given either in the isomer D-chiroinositol (7) or in the myo-inositol isomer (8).”
BackgroundVanky, E., Stridsklev, S., Heimstad, R., Romundstad, P., Skogøy, K., Kleggetveit, O., Hjelle, S., von Brandis, P., Eikeland, T., Flo, K., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0853 · Cited by 315
Genazzani, A. D., Lanzoni, C., Ricchieri, F., & Jasonni, V. M. (2008) · Gynecological Endocrinology · doi:10.1080/09513590801893232 · Cited by 221 · cited 1×
“Another substance primarily used in polycystic ovary syndrome (PCOS), with the aim of lowering hyperinsulinemia and restoring ovarian function, was inositol; it was given either in the isomer D-chiroinositol (7) or in the myo-inositol isomer (8).”
BackgroundGiordano, D., Corrado, F., Santamaria, A., Quattrone, S., Pintaudi, B., Di Benedetto, A., & D'Anna, R. (2011) · Menopause · doi:10.1097/gme.0b013e3181e8e1b1 · Cited by 89
Self-citation
Cited by
Potential role and therapeutic interests of myo-inositol in metabolic diseases
Croze, M. L., & Soulage, C. O. (2013) · Biochimie · doi:10.1016/j.biochi.2013.05.011 · Cited by 578
Gestational diabetes mellitus: an updated overview
Chiefari, E., Arcidiacono, B., Foti, D., & Brunetti, A. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0607-5 · Cited by 522
Treatments for women with gestational diabetes mellitus: an overview of Cochrane systematic reviews
Martis, R., Crowther, C. A., Shepherd, E., Alsweiler, J., Downie, M. R., & Brown, J. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012327.pub2 · Cited by 159
Gestational Diabetes Mellitus and Preeclampsia: Correlation and Influencing Factors
Yang, Y., & Wu, N. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.831297 · Cited by 155
Griffith, R. J., Alsweiler, J., Moore, A. E., Brown, S., Middleton, P., Shepherd, E., & Crowther, C. A. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012394.pub3 · Cited by 149
Metadata
- Authors
- D’Anna, R., Scilipoti, A., Giordano, D., Caruso, C., Cannata, M. L., Interdonato, M. L., Corrado, F., & Di Benedetto, A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-03-14
- Volume
- 36
- Issue
- 4
- Pages
- 854-857
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2010698464
- Cited by
- 166
- References
- 8
- FWCI
- 13.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: myo-Inositol Supplementation and Onset of Gestational Diabetes Mellitus in Pregnant Women With a Family History of Type 2 Diabetes. https://app.cochat.ai/papers/10.2337/dc12-1371
- The paper
- D’Anna, R., Scilipoti, A., Giordano, D., Caruso, C., Cannata, M. L., Interdonato, M. L., Corrado, F., & Di Benedetto, A. (2013). myo-Inositol Supplementation and Onset of Gestational Diabetes Mellitus in Pregnant Women With a Family History of Type 2 Diabetes. Diabetes Care. https://doi.org/10.2337/dc12-1371
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.